The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Im still out, but anybody know how the US election could affect this share. I really like Hikma and keen to get back in.
It takes a lot of consideration to jump off this share.
My take was the two chart patterns W and M.
Just a test
Sold up due to bad vibes from the 5 month low of the Ftse 100. if I'm right ill buy them back, if I'm not, I did alright here. 2300's to 2700, then some trading 25 back to 26 a couple of times. Hard to see any blue chip making new highs in the current climate.
Thanks Owls. I subscribed with IC for three or so years and found it broadened my knowledge of stocks but the information was freely available if you follow the likes of Richard Beddard. What has made a huge difference has been stronger technical understanding - the key indicators that stock pickers use to make new purchases. It was the reason I piled into Hikma a few years ago.
Well done. I think I read somewhere that over the last 20 years you would have trebled your money if you were fully invested but if you missed out on the best 20 days you would have lost money.
Hi Owls, I took your advice and trebled my holding in Aminex and got lucky. You are quite right cash is trash while it’s sat around doing nothing.
HIKMA is one of IC'S 2 tips of the week. They get a bit of bad press but generally their tips are quite good.
FANTOM, you may be right, you may be wrong. Nobody knows including you. If you are so confident that there is going to be a big fall then you would be better shorting the FTSE rather than holding cash.
Cheers Dartron, I’m happy to have been invested through the £8 times and with dividends doubled my £40k. There is a big fall on the radar Owls mark my words. Then the cash will come in handy.
Timing the market is impossible. Cash doesn't make you anything.
Best of luck Fantom. Totally understand your reasons for selling. I bought more today at the afternoon low - albeit to replace some I sold last week. Thought the sell off yesterday and today was over done.
I decided to bail out of Hikma today. Not because I don’t like the company but because of general market weakness and the negativity could impact further on the share price. Holding cash for now and seeing how things pan out.
Yep, Im up around 8% currently on quite a large investment. The dividend must be paid soon too (21st Sept?).
Also impressive when compared to the index which went down while most of this rise happened.
Also very encouraging recently some of the brokers upgrades:
GOLDMAN SACHS RAISES HIKMA PHARMA TO 'BUY' ('NEUTRAL') - TARGET 3,115 (2,600) PENCE
Hikma Pharmaceuticals: Barclays upgrades to overweight with a target price of 2,800.0p.
I see this exceeding 2700p
Excellent recovery over the last couple of months, hit a new 12 month high today, usually a good sign.
Sold the shares I bought at 21.80 today, as I feel this is still selling off. I still have my long term holding, and I will buy some back if it goes below £22.50. I think this will do well as a long term investment, but perhaps it is not going to rise just yet. The stamp duty and high share price does not help either.
Spent yesterday dithering over selling half my holding but glad i held on. As you say Dartron the sell off made no sense, just hope it wasn't my pension fund selling them off
Great set of results, dividend up 14%. SP up 7% currently. Been a testing couple of months as the SP sold off and sold off, even yesterday. Makes no sense to me. Always thought the results and outlook would be impressive. Glad I got the chance to load up in the 21's.
Hopefully building up towards the results on Friday. I have bought more today, to lower my average. A lot of brokers have this north of £26. We will see on Friday!
Someone wants rid of a lot of these shares. Even though the price is up today, there is still more selling than buying. I want to buy back in as sold out half my holding when I saw it was going down. But I dont think it has turned yet. Makes no sense to me, other than I think money is leaving the market and this is not necessarily a reflection on Hikma?
The dividend may have doubled but from a low base. At 1.7% it is well below the FTSE100 average so not really an income stock.
I bought this based on momentum but this appears to have reversed, down over 20% in the last couple of months.
Over the last five years, the dividend payout has doubled. You don’t see that kind of growth within the FTSE 100 index very often. Moreover, dividend coverage is very high. This suggests there could be plenty more growth to come. Hikma shares currently trade on a forward-looking P/E ratio of about 17. I see that valuation as attractive. I think this stock has the potential to deliver both capital gains and dividends.
Managed to free up some capital and bought at 21.89.
Defies sense this one. Would have thought £23 was the minimum this should be worth by virtue of the placing shares and the buy back. All I can say is that I am glad to still be able to buy i at low £22's. Desperately hoping I can take some profit somewhere else before this chance is gone.
Hikma Pharmatheuticals: Morgan Stanley upgrades to overweight with a target price of 2,600.0p.
Hopefully they dont join the club and scrap the dividend.
Yep, been my worst performing share in June but I suppose something has to be.